Redeye comments on BioInvent's Q3 report, which presented new data for the subcutaneous version of B...
Exel’s Q3 figures disappointed due to the continued demand softness, however EBIT has plenty of pote...
Redeye comments on Tessin’s Q3 results, which were weaker than expected.
Redeye provides an update following CLS’s Q3 2024 report.
Redeye returns following IRLAB's Q3 report and recent news in the company.
We expect Suominen to deliver another quarter of improving profitability, driven by increased volume...
Q3e: Germany continues to weigh, US expected to be stable Lowered estimates in Germany on prolonged ...
Q3e sales -7% y-o-y (-12% org.), adj. EBITA 5.4% (8.
Redeye resumes coverage of Nanologica following the announced outcome of its rights issue, which sec...
Enrad AB:s nettoomsättning på ca 8,0 MSEK under kv3 2024 överensstämde med vår prognos före rapporte...
Loihde’s Q3 beat our estimates, offset by expectations of a slower Q4.
Marimekko reports its Q3 results on 6th of November.
Q3 2024 profit before loan losses came in at DKK 66m, DKK 7m (10%) below our estimate.
Redeye comments on the steps to introduce Scibase solutions to other countries further.
Redeye returns with a more in-depth take on Devyser’s Q3 report.
